Listed by the USPTO as MARVICH, MARIA
Tech Center 1600 • Art Units: 1631 1633 1634 1645
This examiner grants 55% of resolved cases
MARVICH, MARIA is assigned to Tech Center 1600 and Art Unit 1631. The profile records 995 resolved cases and an allowance rate of 54.9%. The interview lift is 27.8%, showing a meaningful relationship between interview activity and allowance outcomes within this record, although it remains below the overall allowance rate.
The median time to allowance is 1472 days, so applicants should account for an extended prosecution horizon when setting portfolio expectations. The leading companies are Janssen Pharmaceuticals Inc., Massachusetts Institute of Technology, and Synplogen Co., Ltd. The leading firms are Knobbe, Martens, Olson & Bear, LLP, CANTOR COLBURN LLP, and Johnson, Marcou, Isaacs & Nix, LLC. The large case base supports using these indicators in preparation and workflow planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17932633 | Modified EC7 Cells Having Low Toxicity to Viral Production Payloads | Final Rejection | NantBio, Inc. |
| 18545113 | ONCOLYTIC VIRUS AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17813843 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | Non-Final OA | Novartis AG |
| 17839667 | MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION | Final Rejection | Yeda Research and Development Co. Ltd. |
| 19449304 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 17767970 | CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17768591 | COMPOSITIONS AND METHODS FOR USING ALTERNATIVE SPLICING TO CONTROL SPECIFICITY OF GENE THERAPY | Final Rejection | The Johns Hopkins University |
| 18705359 | METHOD FOR PRODUCING MILK LIKE PRODUCTS | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | Non-Final OA | PharmaEssentia Corporation |
| 18019423 | Molecular Targets for Modulation of Dissociative and Associative States | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18612441 | TREATMENT AGENT FOR HAIR DAMAGE | Final Rejection | TOHOKU UNIVERSITY |
| 17694841 | Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies | Non-Final OA | The Children's Hospital of Philadelphia |
| 18268533 | MICROCARRIER FOR CELL CULTURE AND CELL CULTURE METHOD | Non-Final OA | SEKISUI CHEMICAL CO., LTD. |
| 18875094 | CAR-EXPRESSING PLURIPOTENT STEM CELL-DERIVED NEUTROPHILS LOADED WITH DRUG NANOPARTICLES AND USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 18031486 | Engineered Cells for Increased Collagen Production | Non-Final OA | Northeastern University |
| 18574777 | ENGINEERED NODAVIRAL CARGO DELIVERY SYSTEMS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18051936 | MINIATURIZED DYSTROPHINS HAVING SPECTRIN FUSION DOMAINS AND USES THEREOF | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18847004 | DELIVERY METHODS USING PLATELETS | Non-Final OA | Children's Hospital Medical Center |
| 18701144 | INNER EAR ORGANOIDS HAVING IMPROVED HAIR CELL DIFFERENTIATION ABILITY AND METHOD FOR PRODUCING SAME | Final Rejection | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18748156 | HYPOVENTILATION PHYSICAL MODELS AND APPLICATIONS THEREOF | Non-Final OA | The University of Hong Kong |
| 17904229 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | Non-Final OA | Temple University-Of The Commonwealth System of Higher Education |
| 17050601 | THERAPEUTIC GENOME EDITING IN X-LINKED HYPER IGM SYNDROME | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18074107 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION | Non-Final OA | The Children's Medical Center Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.9% of resolved applications examined by Maria Marvich were allowed (995 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.
This examiner's interview lift is +27.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Maria Marvich took 1,472 days on average from filing to allowance.
Maria Marvich examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).